Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
11.89
-0.08 (-0.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alvotech - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
March 20, 2024
Alvotech just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Alvotech's Earnings: A Preview
March 19, 2024
Via
Benzinga
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024
From
Alvotech
Via
GlobeNewswire
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
March 25, 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alvotech Announces Increase in Number of Own Shares
March 22, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech's Earnings: A Preview
November 27, 2023
Via
Benzinga
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For March 20, 2024
March 20, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via
Benzinga
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024
Alvotech to host Capital Markets Day in Reykjavik and on-line on March 22, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024
From
Alvotech
Via
GlobeNewswire
TEVA Stock Pops 4% as Teva Receives FDA Approval
February 26, 2024
Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.
Via
InvestorPlace
Exposures
Product Safety
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
February 26, 2024
FDA-approved Simlandi (adalimumab-ryvk): a high-concentration biosimilar to Humira for rheumatoid arthritis, psoriasis, and more.
Via
Benzinga
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 15, 2024
From
Alvotech
Via
GlobeNewswire
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
January 29, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024
From
Alvotech
Via
GlobeNewswire
3 mid-caps under $20 that Wall Street loves
January 23, 2024
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024
From
Alvotech
Via
GlobeNewswire
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
November 29, 2023
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
November 28, 2023
From
Alvotech
Via
GlobeNewswire
Earnings Scheduled For November 28, 2023
November 28, 2023
Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion.
Via
Benzinga
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
November 21, 2023
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.